AM-251 (drug)

AM-251 is a drug that acts as a selective antagonist at the cannabinoid receptor CB1. It is used in scientific research and has no currently accepted medical uses, although it is commonly used in research to explore the role of the CB1 receptor in the regulation of body weight, food intake, and energy balance.

Chemistry

AM-251 is a derivative of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide. It is a member of the pyrazole class of cannabinoids and is structurally related to the active component of cannabis, delta-9-tetrahydrocannabinol (THC).

Pharmacology

AM-251 acts as a inverse agonist at the CB1 receptor, meaning it produces effects opposite to those of cannabinoids like THC. It has been shown to decrease food intake and body weight in animal models, suggesting a potential role for CB1 antagonists in the treatment of obesity.

Research

Research on AM-251 has focused on its potential therapeutic uses. Studies have shown that it can reduce food intake and body weight in animal models, and it has been suggested as a potential treatment for obesity. Other research has explored its effects on pain, anxiety, and neurodegenerative disorders, although these areas are still in the early stages of investigation.

Safety

As a research chemical, AM-251 is not approved for use in humans. Its safety profile is not well established, and it should be used with caution.

See also

• Cannabinoid receptor antagonist
• Rimonabant
• Cannabinoid
• Obesity